Peli BioThermal establishes presence in China

23-Feb-2022

China is a significant and growing part the global pharmaceutical manufacturing market, including the production of APIs and generics

Cold chain company Peli BioThermal has announced the opening of its first network station in China. Located in Shanghai, the station will serve global customers of the company’s Crēdo on Demand rental programme.

“China is the second largest pharmaceutical market in the world, and the country has plans to significantly grow its pharmaceutical industry over the next five years,” said Dominic Hyde, VP, Global Services at Peli BioThermal. “Our new network station will make temperature controlled shipping logistics more convenient for customers doing work in the broader Asia-Pacific region.”

China is a significant and growing part the global pharmaceutical manufacturing market, including the production of APIs and generics. Through the ‘Made in China 2025’ plan, the nation aims to further expand its pharma sector, focusing on research and development.

The Shanghai market is home to several of China’s top pharmaceutical manufacturers, Peli says, including Shanghai Pharmaceuticals and Shanghai Fosun Pharmaceutical, and is a base for pharma companies including Pfizer, AstraZeneca and GlaxoSmithKline.

Sign up for your free email newsletter

Shanghai joins the company’s existing network, spanning more than 100 network stations and drop points around the world.

Companies